What question did this study set out to answer?

To retrospectively evaluate and compare the efficacy and safety profiles of first-line gemcitabine plus nab-paclitaxel versus FOLFIRINOX in locally advanced, unresectable pancreatic cancer.

August 1, 2021Pancreas

Gemcitabine Plus Nab-Paclitaxel Versus FOLFIRINOX in Locally Advanced, Unresectable Pancreatic Cancer

View Full Paper

Ask AI

Bookmark

Authors

SAShiho ArimaKagoshima University MKMachiko KawahiraKagoshima University Hospital MSMototsugu ShimokawaYamaguchi University

Discussion

Member takes

Implication

Retrospective study finds similar survival between GnP and FOLFIRINOX in locally advanced pancreatic cancer, suggesting toxicity profiles should guide treatment selection.

Key Points

To retrospectively evaluate and compare the efficacy and safety profiles of first-line gemcitabine plus nab-paclitaxel versus FOLFIRINOX in locally advanced, unresectable pancreatic cancer.
Multicenter retrospective review of medical records from the NAPOLEON study covering patients with locally advanced, unresectable pancreatic cancer treated between December 2013 and March 2017 (N = 63).
Patients received first-line chemotherapy consisting of either gemcitabine plus nab-paclitaxel (n = 47) or FOLFIRINOX (n = 16).
Median overall survival was 15.5 months in the gemcitabine plus nab-paclitaxel group compared to 14.3 months in the FOLFIRINOX group (P = 0.60).
Median progression-free survival was 8.8 months with gemcitabine plus nab-paclitaxel versus 8.1 months with FOLFIRINOX (P = 0.51).
Both chemotherapy regimens were generally well tolerated, though patients receiving FOLFIRINOX experienced more severe anorexia than those receiving gemcitabine plus nab-paclitaxel.

Cite This Study

Arima et al. (2021) studied this question.

synapsesocial.com/papers/6a904b411dcd98381b840064 https://doi.org/10.1097/mpa.0000000000001859

View Full Paper

Ask AI

Bookmark

Implication

Retrospective study finds similar survival between GnP and FOLFIRINOX in locally advanced pancreatic cancer, suggesting toxicity profiles should guide treatment selection.

Gemcitabine Plus Nab-Paclitaxel Versus FOLFIRINOX in Locally Advanced, Unresectable Pancreatic Cancer

Discussion

Member takes

Implication

Key Points

Cite This Study

Gemcitabine Plus Nab-Paclitaxel Versus FOLFIRINOX in Locally Advanced, Unresectable Pancreatic Cancer

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider